{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:17:12Z","timestamp":1790806632615,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Cleveland Clinic Department of Radiation Oncology"},{"DOI":"10.13039\/100012380","name":"Lerner Research Institute, Cleveland Clinic","doi-asserted-by":"publisher","award":["RPC 326"],"award-info":[{"award-number":["RPC 326"]}],"id":[{"id":"10.13039\/100012380","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cleveland Clinic Imaging Institute"},{"name":"Blue Earth Diagnostics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11060-023-04377-5","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T06:01:40Z","timestamp":1687327300000},"page":"647-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["18F-fluciclovine PET\/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study"],"prefix":"10.1007","volume":"163","author":[{"given":"Martin C.","family":"Tom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"DiFilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Obuchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Smile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin S.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene H.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilyana","family":"Angelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza M.","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Peereboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen H. J.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"issue":"3","key":"4377_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ijrobp.2018.10.038","volume":"103","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ et al (2019) Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials. Int J Radiat Oncol Biol Phys 103(3):618\u2013630","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4377_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4):401\u2013409","journal-title":"JAMA"},{"issue":"10","key":"4377_CR3","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3174\/ajnr.A2668","volume":"32","author":"TR Patel","year":"2011","unstructured":"Patel TR et al (2011) A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. AJNR Am J Neuroradiol 32(10):1885\u20131892","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"4377_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijrobp.2013.05.015","volume":"87","author":"ST Chao","year":"2013","unstructured":"Chao ST et al (2013) Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys 87(3):449\u2013457","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"4377_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/fon.13.271","volume":"10","author":"AJ Walker","year":"2014","unstructured":"Walker AJ et al (2014) Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression? Future Oncol 10(7):1277\u20131297","journal-title":"Future Oncol"},{"key":"4377_CR6","doi-asserted-by":"publisher","first-page":"e903","DOI":"10.1016\/j.wneu.2019.11.037","volume":"134","author":"H Borghei-Razavi","year":"2020","unstructured":"Borghei-Razavi H et al (2020) Pathologic correlation of cellular imaging using apparent diffusion coefficient quantification in patients with brain metastases after gamma knife radiosurgery. World Neurosurg 134:e903\u2013e912","journal-title":"World Neurosurg"},{"issue":"5","key":"4377_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/neuonc\/noz003","volume":"21","author":"N Galldiks","year":"2019","unstructured":"Galldiks N et al (2019) PET imaging in patients with brain metastasis-report of the RANO\/PET group. Neuro Oncol 21(5):585\u2013595","journal-title":"Neuro Oncol"},{"issue":"5","key":"4377_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3171\/jns.2003.98.5.1056","volume":"98","author":"N Tsuyuguchi","year":"2003","unstructured":"Tsuyuguchi N et al (2003) Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 98(5):1056\u20131064","journal-title":"J Neurosurg"},{"issue":"5","key":"4377_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2967\/jnumed.107.048082","volume":"49","author":"Y Terakawa","year":"2008","unstructured":"Terakawa Y et al (2008) Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49(5):694\u2013699","journal-title":"J Nucl Med"},{"issue":"7","key":"4377_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132515","volume":"10","author":"R Minamimoto","year":"2015","unstructured":"Minamimoto R et al (2015) Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment. PLoS\u00a0One 10(7):e0132515","journal-title":"PLoS\u00a0One"},{"issue":"8","key":"4377_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3174\/ajnr.A5252","volume":"38","author":"N Tomura","year":"2017","unstructured":"Tomura N et al (2017) Differentiation between treatment-induced necrosis and recurrent tumors in patients with metastatic brain tumors: comparison among (11)C-methionine-PET, FDG-PET, MR permeability imaging, and MRI-ADC-preliminary results. AJNR Am J Neuroradiol 38(8):1520\u20131527","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"4377_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12885-017-3702-x","volume":"17","author":"S Yomo","year":"2017","unstructured":"Yomo S, Oguchi K (2017) Prospective study of (11)C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment. BMC Cancer 17(1):713","journal-title":"BMC Cancer"},{"issue":"1","key":"4377_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/jnumed.113.121418","volume":"55","author":"KJ Lizarraga","year":"2014","unstructured":"Lizarraga KJ et al (2014) (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med 55(1):30\u201336","journal-title":"J Nucl Med"},{"issue":"1","key":"4377_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-014-2886-4","volume":"42","author":"F Cicone","year":"2015","unstructured":"Cicone F et al (2015) Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. Eur J Nucl Med Mol Imaging 42(1):103\u2013111","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"4377_CR15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2967\/jnumed.112.103325","volume":"53","author":"N Galldiks","year":"2012","unstructured":"Galldiks N et al (2012) Role of O-(2-(18)F-fluoroethyl)-l-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 53(9):1367\u20131374","journal-title":"J Nucl Med"},{"issue":"1","key":"4377_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13014-016-0713-8","volume":"11","author":"A Romagna","year":"2016","unstructured":"Romagna A et al (2016) Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET-PET overcome diagnostic uncertainties? Radiat Oncol 11(1):139","journal-title":"Radiat Oncol"},{"issue":"2","key":"4377_CR17","first-page":"281","volume":"19","author":"G Ceccon","year":"2017","unstructured":"Ceccon G et al (2017) Dynamic O-(2\u201318F-fluoroethyl)-l-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol 19(2):281\u2013288","journal-title":"Neuro Oncol"},{"issue":"5","key":"4377_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2967\/jnumed.117.204032","volume":"59","author":"EE Parent","year":"2018","unstructured":"Parent EE, Schuster DM (2018) Update on (18)F-fluciclovine PET for prostate cancer imaging. J Nucl Med 59(5):733\u2013739","journal-title":"J Nucl Med"},{"issue":"6","key":"4377_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00259-019-04433-1","volume":"47","author":"L Michaud","year":"2020","unstructured":"Michaud L et al (2020) (18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors. Eur J Nucl Med Mol Imaging 47(6):1353\u20131367","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"4377_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/RLU.0000000000002641","volume":"44","author":"TV Bogsrud","year":"2019","unstructured":"Bogsrud TV et al (2019) 18F-fluciclovine PET\/CT in suspected residual or recurrent high-grade glioma. Clin Nucl Med 44(8):605\u2013611","journal-title":"Clin Nucl Med"},{"issue":"7","key":"4377_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/RLU.0000000000002610","volume":"44","author":"A Karlberg","year":"2019","unstructured":"Karlberg A et al (2019) 18F-FACBC PET\/MRI in diagnostic assessment and neurosurgery of gliomas. Clin Nucl Med 44(7):550\u2013559","journal-title":"Clin Nucl Med"},{"issue":"1","key":"4377_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13550-018-0415-3","volume":"8","author":"EE Parent","year":"2018","unstructured":"Parent EE et al (2018) [(18)F]Fluciclovine PET discrimination between high- and low-grade gliomas. EJNMMI Res 8(1):67","journal-title":"EJNMMI Res"},{"issue":"2","key":"4377_CR23","first-page":"85","volume":"5","author":"N Tsuyuguchi","year":"2017","unstructured":"Tsuyuguchi N et al (2017) Diagnosis of brain tumors using amino acid transport PET imaging with (18)F-fluciclovine: a comparative study with l-methyl-(11)C-methionine PET imaging. Asia Ocean J Nucl Med Biol 5(2):85\u201394","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"1","key":"4377_CR24","first-page":"10","volume":"5","author":"T Wakabayashi","year":"2017","unstructured":"Wakabayashi T et al (2017) Diagnostic performance and safety of positron emission tomography using (18)F-fluciclovine in patients with clinically suspected high- or low-grade gliomas: a multicenter phase IIb trial. Asia Ocean J Nucl Med Biol 5(1):10\u201321","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"9","key":"4377_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s12149-016-1102-y","volume":"30","author":"A Kondo","year":"2016","unstructured":"Kondo A et al (2016) Phase IIa clinical study of [(18)F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med 30(9):608\u2013618","journal-title":"Ann Nucl Med"},{"issue":"2","key":"4377_CR26","first-page":"152","volume":"7","author":"F Henderson Jr","year":"2020","unstructured":"Henderson F Jr et al (2020) (18)F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling. Neurooncol Pract 7(2):152\u2013157","journal-title":"Neurooncol Pract"},{"key":"4377_CR27","doi-asserted-by":"publisher","first-page":"989 e1","DOI":"10.1016\/j.wneu.2017.08.085","volume":"108","author":"A Karlberg","year":"2017","unstructured":"Karlberg A et al (2017) Multimodal (18)F-fluciclovine PET\/MRI and ultrasound-guided neurosurgery of an anaplastic oligodendroglioma. World Neurosurg 108:989 e1-989 e8","journal-title":"World Neurosurg"},{"key":"4377_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.brainres.2013.08.037","volume":"1535","author":"M Ono","year":"2013","unstructured":"Ono M et al (2013) Comparative evaluation of transport mechanisms of trans-1-amino-3-[(1)(8)F]fluorocyclobutanecarboxylic acid and l-[methyl-(1)(1)C]methionine in human glioma cell lines. Brain Res 1535:24\u201337","journal-title":"Brain Res"},{"issue":"1","key":"4377_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41824-021-00101-6","volume":"5","author":"K Johannessen","year":"2021","unstructured":"Johannessen K et al (2021) (18)F-FACBC PET\/MRI in the evaluation of human brain metastases: a case report. Eur J Hybrid Imaging 5(1):7","journal-title":"Eur J Hybrid Imaging"},{"issue":"1","key":"4377_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13550-020-00739-6","volume":"10","author":"EE Parent","year":"2020","unstructured":"Parent EE et al (2020) [(18)F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis. EJNMMI Res 10(1):148","journal-title":"EJNMMI Res"},{"issue":"Suppl 1","key":"4377_CR31","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL et al (2009) From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-S150","journal-title":"J Nucl Med"},{"issue":"6","key":"4377_CR32","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270\u2013e278","journal-title":"Lancet Oncol"},{"issue":"10","key":"4377_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.7150\/thno.5629","volume":"3","author":"B Bai","year":"2013","unstructured":"Bai B, Bading J, Conti PS (2013) Tumor quantification in clinical positron emission tomography. Theranostics 3(10):787\u2013801","journal-title":"Theranostics"},{"issue":"1","key":"4377_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2967\/jnumed.115.154757","volume":"57","author":"B Aklan","year":"2016","unstructured":"Aklan B et al (2016) Impact of point-spread function modeling on pet image quality in integrated PET\/MR hybrid imaging. J Nucl Med 57(1):78\u201384","journal-title":"J Nucl Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04377-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T10:07:59Z","timestamp":1690884479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04377-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4377"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04377-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"14 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MCT: Honoraria from ViewRay. Institutional research funding from Blue Earth Diagnostics Ltd. Personal fees from Elsevier. FPD: None. SEJ: None. JHS: Scientific advisory board for and consulting fees from Philips, Novocure. Leadership role with American Board of Radiology, International Radiosurgery Research Foundation, International Stereotactic Radiosurgery Society. NAO: Grants or contracts from Quantitative Imaging Biomarker Alliance. Honoraria from NCI Clinical Imaging Steering committee and ECOG-ACRIN DBMB. TDS: None. ESM: None. JSY: None. GHB: Monteris Medical, Inc. Plymouth, Minnesota. LA: None. AMM: None. SSH: None. GW: None. SJ: None. DMP: None. GHJS: None. MSA: Receipt of grants\/research supports: Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, Merck. Receipt of honoraria or consultation fees: Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, AnHeart Therapeutics, Caris Lifesciences, Theraguix, Pyramid biosciences. Scientific advisory board: Modifi bio, Pyramid Biosciences, Cairn Therapeutics, Bugworks. Stock shareholder: Doctible, Mimivax, Cytodyn, MedInnovate Advisors LLC. STC: Honoraria from Varian Medical Systems and Blue Earth Diagnostics. Travel support from Blue Earth Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}